Antibody-drug conjugates (ADCs) are a newer type of cancer treatment designed to target cancer cells more directly.
An ADC works like a guided delivery system:
- The antibody finds and attaches to a specific protein on a cancer cell.
- A linker holds the parts together.
- The payload is a strong cancer-killing drug.
An ADC is made up of an Antibody, a Linker and a Payload.
Once the ADC attaches to the cancer cell, it is taken inside the cell. The drug is then released and helps destroy the cancer from within. In some cases, nearby cancer cells may also be affected.
ADCs are already used to treat some cancers. For prostate cancer, they are still being studied in clinical trials, mainly for men with advanced disease.
Speak to your Doctor to see if ADC clinical trials could be a good fit for you.
Not all prostate cancers have the same targets, so your care team may review your cancer stage, past treatments, and test results to see if an ADC trial could be an option. Some trials require testing your tumor first.
Like all cancer treatments, ADCs can cause side effects. Common ones include tiredness, nausea, and low blood counts. Less commonly, they may affect the eyes, nerves, or lungs. Always tell your care team about new or worsening symptoms.
You can ask your care team if ADC clinical trials are available for you, what testing is needed, how treatment is given, and what side effects to expect.
Clinical Trial Spotlights
ADCs are designed to deliver a potent drug more directly to cancer cells. Clinical trials help researchers understand who benefits most, the best way to give the treatment, and which side effects to monitor closely.
IDeate Prostate is a clinical trial program evaluating ifinatamab deruxtecan (MK-2400; I-DXd), a B7-H3–targeting ADC, for men with metastatic castration-resistant prostate cancer (mCRPC). B7-H3 is a protein found on many cancer cells and is being studied as a treatment target.
IDeate Prostate01 is a Phase 3 study designed to compare MK-2400 with docetaxel plus a corticosteroid in men with previously treated mCRPC. Researchers will evaluate outcomes such as how long the cancer stays under control and overall survival, while closely tracking safety.
IDeate Prostate02 is a Phase 1/2 umbrella study evaluating MK-2400 alone and in combination regimens to help identify the best dose and the most promising approaches.
>> View these and more Merck Sponsored Trials at PHENTrials.com
More Clinical Trials on PHENTrials.com
ProstACT
The study is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC) that expresses PSMA and has progressed despite prior treatment with hormone therapy.
XALute
XALute is a research study for men with advanced prostate cancer (cancer has spread to other parts of the body) who have already been treated with chemotherapy.
Mevpro-3
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
Find-Your-Trial
PHEN’s Find Your Trial (FYT) search tool connects patients with prostate cancer clinical trials based on their diagnosis and location.